Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission |
| Type de publication | Journal Article |
| Year of Publication | 2018 |
| Auteurs | Saraceni F, Labopin M, Hamladji R-M, Mufti G, Socie G, Shimoni A, Delage J, Deconinck E, Chevallier P, Blaise D, Sanz J, Huynh A, Forcade E, Savani BN, Mohty M, Nagler A, Europ ALeukemia W |
| Journal | ONCOTARGET |
| Volume | 9 |
| Pagination | 3379-3393 |
| Date Published | JAN 9 |
| Type of Article | Article |
| Mots-clés | acute myeloid leukemia (AML), Allogeneic transplantation, busulfan-fludarabine (BF), myeloablative conditioning (MAC), thiotepa-busulfan-fludarabine (TBF) |
| Résumé | {Background: A preparatory regimen consisting of thiotepa-busulfan-fludarabine (TBF) has been associated with reduced relapse in patients with haematological malignancies after haploidentical and cord blood transplants; however, few data exist regarding TBF conditioning in sibling (MSD) and unrelated donor (URD) transplants for AML. Results: Among patients receiving a myeloablative (MAC) regimen, TBF-MAC was associated with significantly lower relapse (HR 0.47 |
| DOI | 10.18632/oncotarget.23273 |